Artificial Life launches GluCoMo app for diabetics
LOS ANGELES A leading provider of award-winning mobile 3G technology and applications recently launched a mobile app for diabetics.
Artificial Life said its app GluCoMo (short for glucose monitor) is an electronic diary and reminder system that keeps track of many diabetes-related activities in one centralized mobile hub. The comprehensive readings recorded within the app include: blood sugar level, insulin intake, weight, pulse, physical activity, dietary intake, blood pressure and medication intake. GluCoMo users also may adjust their activities by reviewing their entry history through easy-to-use informative graph visualizations, and set up automatic reminders to alert themselves of different health-related activities, Artificial Life said.
GluCoMo is available for download on Apple’s app store.
Perrigo gets approval for generic Aldara
ALLEGAN, Mich. The Food and Drug Administration has approved Perrigo’s generic drug for treating skin diseases, the drug maker said Wednesday.
The FDA approved Perrigo’s imiquimod cream in the 5% strength. The drug is a generic version of Graceway Pharmaceuticals’ Aldara.
The drug is used to treat actinic keratoses on the face and scalp, superficial basal cell carcinoma and external genital and perianal warts in patients ages 12 years and older.
GSK inks deal with Lonza, announces CFO’s exit
LONDON Swiss drug maker Lonza will help British drug maker GlaxoSmithKline manufacture five biotech drugs in early- and mid-stage clinical trials, the two companies said Wednesday.
Lonza will manufacture clinical trial batches of the drugs, all monoclonal antibodies in phase-1 and phase-2 testing, and provide additional access to manufacturing capacity so GSK can fulfill future demands. The two companies said other details of the agreement remain confidential.
“We believe this is a critical step in the ongoing and future success of GSK in biopharmaceuticals,” GSK head of biopharmaceutical research and development Ian Tomlinson said.
Tomlinson said the company’s goal was to have a biopharmaceutical portfolio that consistently exceeded 20% of its research and development pipeline by 2015.
In other news, the company said that CFO and executive director Julian Heslop would retire at the end of March 2011. Goldman Sachs executive Simon Dingemans will be appointed CFO designate and executive director in January.